Here's a 33c ASX stock that could have the potential to reach $1+

Bell Potter is tipping huge returns for this small cap.

| More on:

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

At the small side of the market there are opportunities to generate incredible returns.

However, it is worth remembering that the risks are also very high.

So, the (potentially) cheap stock that I am going to talk about in this article would only be suitable for investors with a high tolerance for risk.

That stock is Paradigm Biopharmaceuticals Ltd (ASX: PAR), which is currently trading at 32.5 cents. This is well short of the late-stage drug development company's 52-week high of $1.68.

But one broker that believes it has the potential to return close to those lofty levels is Bell Potter.

According to a recent note, the broker has a speculative buy rating and $1.40 price target on its shares. This implies potential upside of approximately 325% for investors over the next 12 months.

To put that into context, if Bell Potter is on the money with its recommendation, a $10,000 investment would turn into $42,500.

Why could Paradigm be a cheap ASX stock?

Bell Potter highlights that the company is well funded and not far off launching its treatment for osteo arthritis of the knee.

In respect to its treatment, the broker appears very excited by its potential. It said:

MRI quantitative data demonstrated that compared to placebo, patients on drug experience a) an increase in cartilage volume and thickness from baseline, most notably in the medial compartment where the highest proportion (72%) of knee OA occurs; b) an average 17% reduction in bone marrow lesion volume; and c) a reduction in inflammation (synovitis). As far as we are aware no other molecule has demonstrated a capability to apparently halt disease progression, let alone regenerate cartilage.

In our view the findings are strongly supportive of future commercial adoption and are likely to enhance upcoming discussion with both regulators and commercialisation partners.

In light of this, the broker believes the risk/reward from an investment in this cheap ASX stock is compelling for investors. It concludes:

PAR continues to expect to commence dosing in the phase 3 program in 1Q CY24. The company is funded though 1Q CY2024 and is yet to partner in a single region or indication. PAR intends to proceed with a provisional approval application for iPPS in Australia, which if successful may see the drug on market in 2025. Valuation is maintained at $1.40 and we retain our Buy (Speculative rating). There are no changes to earnings. The next major catalysts include potential non dilutive funding deal(s).

Should you invest $1,000 in Allkem right now?

Before you buy Allkem shares, consider this:

Motley Fool investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now... and Allkem wasn't one of them.

The online investing service he’s run for over a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

And right now, Scott thinks there are 5 stocks that may be better buys...

See The 5 Stocks *Returns as of 30 April 2025

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A man has a surprised and relieved expression on his face. as he raises his hands up to his face in response to the high fluctuations in the Galileo share price today
Healthcare Shares

Guess which ASX All Ords stock is rocketing 58% on big US news

What is getting investors excited today? Let's find out.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

3 reasons to buy this quality ASX 200 healthcare share today

A leading expert expects this outperforming ASX 200 healthcare share will keep running hot.

Read more »

A woman reclines in a comfortable chair while she donates blood holding a pumping toy in one hand and giving the thumbs up in the other as she is attached to a medical machine to collect her blood donation.
Healthcare Shares

Brokers tip 4 ASX 200 healthcare shares to buy now

Healthcare is a defensive sector that can provide useful cover for investors when the market is volatile.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

How Trump's tariffs have created 'upside potential' for CSL shares

A leading expert says CSL shares are now looking ‘cheap’.

Read more »

Shot of a young scientist looking stressed out while working on a computer in a lab.
Healthcare Shares

Telix shares crash 8% on US FDA blow

This high-flying stock has been hit with some bad news.

Read more »

A man wakes up happy with a smile on his face and arms outstretched.
Healthcare Shares

ResMed shares jump 8% on strong Q3 update

It was yet another strong quarter from this high-quality company.

Read more »

A woman jumps for joy with a rocket drawn on the wall behind her.
Healthcare Shares

Guess which ASX All Ords stock is up 10% on big news

This high-flying stock just can't stop rising. What's going on?

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

Telix shares rocket 15% on stellar Q1 sales update

Let's see how the company performed during the three months.

Read more »